At the IGTP TODAY

News

- Innovation, Research

A new IGTP spin-off to develop a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

Researchers from the Germans Trias i Pujol Research Institute (IGTP) together with doctors from the hospital have developed a medical device to improve the diagnostics and prognostics of acute ischaemic stroke. The objective of the technology is to optimize the current clinical algorithm for this type of ictus so that medical staff can take the correct decisions for each patient, before and after admission to hospital. To develop the medical device the spin-off company Time is Brain, led by Dr Alicia Martínez-Piñeiro has been created by the IGTP.

- Projects, Research

Germans Trias joins the International study on using the BCG vaccine against COVID-19 in healthcare workers

The Can Ruti Campus joins an ambitious international study to test the possible protective effects of the anti-tuberculosis (BCG) vaccine against COVID-19. In Spain the provision is for 1,000 healthcare workers to take part. The Germans Trias i Pujol Hospital and Research Institute is taking part with Dr Antoni Rosell, Clinical Director of the Thorax Department at the hospital leading the project and the participation of the Pulmonology, Preventive Medicine and Pharmacy together with two research groups working on tuberculosis at the IGTP led by Dr Pere-Joan Cardona and Dr José Domínguez.

- Research

The online HIV test TESTATE joins Hepatitis C screening

The online platform TESTATE (Testyourself) developed by CEEISCAT, has proved very successful in the promotion of the HIV test with a 94% of positive cases following treatment. In a pilot study this system of online request for tests will include the test for the Hepatitis C virus for a thousand users of the platform. The platform allows the centralization of screening strategies in a group vulnerable to infection by this virus to achieve the elimination of the disease as a public health problem in line with WHO objectives

- Institutional, Research

A new paper shows how the CMCiB will shine a new light on neurobiology

A review paper with first author Marc Melià-Sorolla of the Cellular and Molecular Neurobiology Research Group and published in the International Journal of Molecular Sciences highlights a porcine model as the most suitable for stroke research in the future. The CMCiB-IGTP is equipped to carry out this type of research and the group led by Teresa Gasull are already showing the potential of the non-invasive bioimaging technology.

- Research

Will curcumin be a valid therapy for colorectal cancer? Getting to the facts

A new paper reviews the use of curcumin, the active ingredient in turmeric, as a possible combination with current therapies for colorectal cancer, it has been published in Seminars in Cancer Biology. The study, led by Vicenç Ruiz de Porras of the IGTP and ICO shows that research so far points to curcumin being a likely candidate for future cancer therapies.

- Research

New community strategies to promote Health and screening for the micro-elimination of hepatitis C in migrants

The project is a pilot programme for the implementation and validation of the micro-elimination of Hepatitis C based on a community strategy. The validation has focussed on a migrant Pakistani population in Barcelona and the metropolitan area and is now being extended to migrants from other countries where the disease is endemic and to screening for Hepatitis B. The study unites two previously validated strategies to bring education about hepatitis (VHIR) and diagnostics (IGTP) to these vulnerable populations in the community.

- Research

The CMCiB, ready for advanced research on SARS-CoV-2

The Centre for Comparative medicine and Bioimage (CMCiB) of the IGTP has its level 3 biological containment laboratories (BCLL3) ready to receive new projects related to the study of the SARS-CoV-2 virus. These facilities are biological containment areas designed for work on microorganisms that cause infectious diseases, especially those with a high risk of transmission through the diffusion of aerosols.

- Research

Plasmodium vivax parasites are shown to be present and causing changes in bone marrow during Malaria Infections

Three groups from the IGTP have collaborated on a study of the parasite Plasmodium vivax with several Brazilian groups. The paper published in the Journal of Infectious Diseases provides proof of the presence of P. vivax in bone marrow during infections, something which has been controversial until now. They also showed that it disrupts normal red blood cell production, as well as altering the immune response.